Abstract 495P
Background
Osimertinib has been established as standard treatment for patients with advanced EGFR-mutated NSCLC. We assessed the clinical relevance of EGFR mutation tracking in plasma circulating tumor DNA (ctDNA) after initiation of osimertinib therapy in patients who were pre-treated with EGFR-tyrosine kinase inhibitors (TKIs).
Methods
Plasma samples of 106 patients with advanced EGFR-mutated NSCLC who received second-line osimertinib after detection of T790M mutation in plasma ctDNA and/or tissue re-biopsy were collected under osimertinib therapy. Plasma ctDNA was tested for EGFR deletions in exon 19, L858R, L861Q, S768I, T790M and C797S mutations using droplet digital PCR (ddPCR). Primary endpoint was progression-free survival (PFS). Univariate and multivariable Cox proportional hazard models were used to evaluate the risk of progression.
Results
In 57 out of 106 patients plasma samples were available within the first 8 weeks after osimertinib therapy initiation. Within this time frame, the activating mutation remained detectable in plasma of 19/57 patients (33%) and the T790M mutation in 8/57 patients (14%). The C797S mutation was not detectable within 8 weeks after osimertinib start. Patients with persistence of the activating EGFR mutation in plasma ctDNA within 8 weeks after osimertinib initiation had a shorter PFS compared to patients who had lost the activating EGFR mutation (median PFS 3.4 versus 26.9 months; hazard ratio [HR] 6.17, 95% confidence interval [CI] 3.03-12.56, p < 0.0001). Similarly, detection of T790M in plasma ctDNA was also associated with shorter PFS (median PFS 7.0 versus 19.0 months; HR 2.32, 95% CI 1.00-5.37, p = 0.05). Multivariable analysis using a stepwise backward elimination model demonstrated that persistence of activating EGFR mutations and T790M in plasma ctDNA remained significant predictors of shorter PFS after adjusting for clinical parameters and T790M.
Conclusions
Our results show that tracking of activating EGFR mutations during osimertinib therapy is clinically relevant. Detection of activating EGFR mutations in plasma ctDNA 8 weeks after osimertinib initiation predicts shorter PFS of second-line treatment with osimertinib.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
AstraZeneca.
Disclosure
A. Buder: Honoraria (self): AstraZeneca. M.J. Hochmair: Honoraria (self), Advisory / Consultancy: AstraZeneca; Honoraria (self), Advisory / Consultancy: Boehringer Ingelheim. M. Filipits: Advisory / Consultancy, Research grant / Funding (self): AstraZeneca; Advisory / Consultancy: Boehringer Ingelheim. All other authors have declared no conflicts of interest.
Resources from the same session
396P - Determinants of visiting a referral hospital for cervical cancer screening at Uganda Cancer Institute
Presenter: Collins Mpamani
Session: Poster display session
Resources:
Abstract
397P - Development of prediction model for hepatocellular carcinoma in chronic hepatitis B patients
Presenter: Teerapat Ungtrakul
Session: Poster display session
Resources:
Abstract
398P - Planning for future cancer control programs in Uganda: Projections of top five cancers’ incidence in the next decade
Presenter: Judith Asasira
Session: Poster display session
Resources:
Abstract
399P - Prevalence of colorectal cancer risk factors in apparently healthy adults in Suluhan Village, Bali
Presenter: Cindy Trisina
Session: Poster display session
Resources:
Abstract
400P - Female lung cancer: Emerging issue in Bangladesh
Presenter: Muhammad Rafiqul Islam
Session: Poster display session
Resources:
Abstract
402P - Work-related outcomes among cancer survivors in Singapore
Presenter: Chia Jie Tan
Session: Poster display session
Resources:
Abstract
407P - Focal treatments for metastatic soft tissue sarcoma (mSTS) is associated with improved overall survival
Presenter: Ching Tso Chen
Session: Poster display session
Resources:
Abstract
408P - The Asian sarcoma consortium sarcoma preceptorship program: A program evaluation study utilizing the Kirkpatrick model (Level 1 and 2)
Presenter: Fernando Gracieux Jr.
Session: Poster display session
Resources:
Abstract
409P - Integrated genomic and transcriptomic analysis revealed mutagenic patterns of dedifferentiated liposarcoma and leiomyosarcoma in Chinese patients
Presenter: Yuhong Zhou
Session: Poster display session
Resources:
Abstract
410P - Treatment patterns and outcomes of elderly patients with metastatic soft tissue sarcomas (mSTS)
Presenter: Yu-ju Kuo
Session: Poster display session
Resources:
Abstract